The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules,etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that contain any of such B7-H3-binding molecules, and to methods involving the use of any of such B7-H3-binding molecules in the treatment of cancer and other diseases and conditions. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a “B7-H3-ADC”). The invention is also directed to pharmaceutical compositions that contain suchB7-H3-ADCs, and to methods involving the use of any of suchB7-H3-ADCs in the treatment of cancer and other diseases and conditions.本發明涉及能夠結合人和非人B7-H3的新穎的B7-H3-結合分子，尤其涉及與非人靈長類動物(例如食蟹猴)的B7-H3具有交叉反應性的這樣的分子。本發明還涉及包含可變輕鏈結構域和/或可變重鏈(VH)結構域的B7-H3-結合分子，所述可變輕鏈結構域和/或可變重鏈(VH)結構域已經被人源化和/或去免疫化，以便在施用至接受受試者後顯示減少的免疫原性。本發明尤其涉及包括雙特異性雙抗體、BiTE、雙特異性抗體、三價結合分子等的雙特異性、三特異性或多特異性B7-H3-結合分子，其包含(i)這類結合B7-H3的可變結構域和(ii)能夠結合至存在於效應細胞表面上的分子的表位元的結構域。本發明也涉及含有任何這類B7-H3-結合分子的藥物組合物，並涉及包括使用任何這類B7-H3-結合分子治療癌症和其他疾病和病況的方法。本發明還尤其涉及一種分子，所述分子包含綴合至至少一個藥物部分的人源化的抗人B7-H3抗體的人B7-H3結合結構域(“B7-H3-ADC”)。本發明還涉及含有這類B7-H3-ADC的藥物組合物，並涉及包括使用任何這類B7-H3-ADC治療癌症和其
